私が好むのは、ウィールオプション戦略を使用して徐々にトレードに参入することです。小さなポジションで現金担保プットを売って割り当てられ、その後ストラングルにフリップして担当株をカバーしたコールを売って、市場方向に対して両方向にレバレッジをかけるための追加の現金担保プットを売ります。例えば、ロシアとウクライナの継続的な紛争により、私は石油価格が低下し続けると信じています。
翻訳済み
![絞首刑用のホイール](https://ussnsimg.moomoo.com/moo-1649854805-70074865-iPhone-1-org.jpg/thumb)
1
2
$デア バイオサイエンス(DARE.US$ Looking good for re-entry tomorrow PM. Would like it to hold 1.99 at its lowest otherwise a bigger dip may come.
![画像](https://ussnsimg.moomoo.com/16402359448491-70074865-web-8f00b204e9800998.png/thumb)
1
$CymaBay Therapeutics(CBAY.US$
Holding some good support at this area long term. Spike in volume and price on 12/17. Has enough cash for approx 34 months after offering of $4/share which closed on the 11/22 I believe. Expecting Phase 2a data for short term still this year with time running out for MBX-2982 drug for Type 1 diabetes. Still undergoing enrollment on their main drug Seladelpar which is used for autoimmune liver disease with great outlook.
Institutional Holdings are around 60%ish+ according to Yahoo Finance/Ortex/and Finviz while Benzinga Pro reports Institutional Holdings at around 22%
Just back 11/11 Raymond James Maintained Strong Buy and raised PT to $14 with the average analyst PT at $11 where all are at Buy+
And a recent SC13G reported TCG Crossover Management having a 7% stake
Furthermore, according to their last earnings call, they will have sufficient funds to continue current operations into 2023 with no mentions of further dilution.
Holding some good support at this area long term. Spike in volume and price on 12/17. Has enough cash for approx 34 months after offering of $4/share which closed on the 11/22 I believe. Expecting Phase 2a data for short term still this year with time running out for MBX-2982 drug for Type 1 diabetes. Still undergoing enrollment on their main drug Seladelpar which is used for autoimmune liver disease with great outlook.
Institutional Holdings are around 60%ish+ according to Yahoo Finance/Ortex/and Finviz while Benzinga Pro reports Institutional Holdings at around 22%
Just back 11/11 Raymond James Maintained Strong Buy and raised PT to $14 with the average analyst PT at $11 where all are at Buy+
And a recent SC13G reported TCG Crossover Management having a 7% stake
Furthermore, according to their last earnings call, they will have sufficient funds to continue current operations into 2023 with no mentions of further dilution.
![画像](https://ussnsimg.moomoo.com/16400590041583-70074865-web-8f00b204e9800998.png/thumb)
![画像](https://ussnsimg.moomoo.com/16400609334295-70074865-web-8f00b204e9800998.png/thumb)
![画像](https://ussnsimg.moomoo.com/16400610894423-70074865-web-8f00b204e9800998.png/thumb)
+6
![画像](https://ussnsimg.moomoo.com/moo-1636392399-70074865-iPhone-1-org.jpg/thumb)
2
$ヴィーナス(VERO.US$ここでこれを受け取ります :)
翻訳済み
$ハイウェイ ホールディングス(HIHO.US$ここで手に入れました。PT1:4.5;PT2:5.07
翻訳済み